» Articles » PMID: 31569508

Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas

Overview
Date 2019 Oct 2
PMID 31569508
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects worldwide, yet the most effective strategies for preventing virus transmission during pregnancy are unknown. We measured the efficacy of human monoclonal antibodies (mAbs) to HCMV attachment/entry factors glycoprotein B (gB) and the pentameric complex, gH/gL-pUL128-131, in preventing infection and spread of a clinical strain in primary placental cells and explants of developing anchoring villi. A total of 109 explants from five first-trimester placentas were cultured, and infection was analyzed in over 400 cell columns containing ~120,000 cytotrophoblasts (CTBs). mAbs to gB and gH/gL, 3-25 and 3-16, respectively, neutralized infection in stromal fibroblasts and trophoblast progenitor cells. mAbs to pUL128-131 of the pentameric complex, 1-103 and 2-18, neutralized infection of amniotic epithelial cells better than mAbs 3-25 and 3-16 and hyperimmune globulin. Select mAbs neutralized infection of cell column CTBs, with mAb 2-18 most effective, followed by mAb 3-25. Treatment of anchoring villi with mAbs postinfection reduced spread in CTBs and impaired formation of virion assembly compartments, with mAb 2-18 achieving better suppression at lower concentrations. These results predict that antibodies generated by HCMV vaccines or used for passive immunization have the potential to reduce transplacental transmission and congenital disease.

Citing Articles

Primary, Secondary, and Tertiary Prevention of Congenital Cytomegalovirus Infection.

Sartori P, Egloff C, Hcini N, Vauloup Fellous C, Perillaud-Dubois C, Picone O Viruses. 2023; 15(4).

PMID: 37112800 PMC: 10146889. DOI: 10.3390/v15040819.


Neutralization Epitopes in Trimer and Pentamer Complexes Recognized by Potent Cytomegalovirus-Neutralizing Human Monoclonal Antibodies.

Ai Y, Wu C, Zhang M, Jaijyan D, Liu T, Zan L Microbiol Spectr. 2022; 10(6):e0139322.

PMID: 36342276 PMC: 9784774. DOI: 10.1128/spectrum.01393-22.


Endothelial Cell Infection by Guinea Pig Cytomegalovirus Is a Lytic or Persistent Infection Depending on Tissue Origin but Requires Viral Pentamer Complex and pp65 Tegument Protein.

Choi K, El-Hamdi N, McGregor A J Virol. 2022; 96(17):e0083122.

PMID: 36000848 PMC: 9472625. DOI: 10.1128/jvi.00831-22.


Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas.

Tabata T, Petitt M, Li J, Chi X, Chen W, Yurgelonis I Vaccines (Basel). 2022; 10(7).

PMID: 35891239 PMC: 9315547. DOI: 10.3390/vaccines10071074.


Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.

Hu X, Wang H, Otero C, Jenks J, Permar S Annu Rev Virol. 2022; 9(1):491-520.

PMID: 35704747 PMC: 10154983. DOI: 10.1146/annurev-virology-100220-010653.


References
1.
Arvin A, Fast P, Myers M, Plotkin S, Rabinovich R . Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004; 39(2):233-9. DOI: 10.1086/421999. View

2.
Tabata T, Petitt M, Fang-Hoover J, Pereira L . Survey of cellular immune responses to human cytomegalovirus infection in the microenvironment of the uterine-placental interface. Med Microbiol Immunol. 2019; 208(3-4):475-485. PMC: 6635015. DOI: 10.1007/s00430-019-00613-w. View

3.
Schampera M, Arellano-Galindo J, Kagan K, Adler S, Jahn G, Hamprecht K . Role of pentamer complex-specific and IgG subclass 3 antibodies in HCMV hyperimmunoglobulin and standard intravenous IgG preparations. Med Microbiol Immunol. 2018; 208(1):69-80. DOI: 10.1007/s00430-018-0558-x. View

4.
Fu T, Wang D, Freed D, Tang A, Li F, He X . Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine. 2012; 30(52):7469-74. DOI: 10.1016/j.vaccine.2012.10.053. View

5.
Wussow F, Chiuppesi F, Contreras H, Diamond D . Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells. Vaccines (Basel). 2017; 5(4). PMC: 5748606. DOI: 10.3390/vaccines5040039. View